Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma has announced that it is working with the business development group of Xinhua Finance, a Chinese financial services and media company, in order to expand its business into the growing Chinese market.
Subscribe to our email newsletter
Xinhua Finance will give Nutra Pharma strategic advice for advancing its business objectives in China, and help the company to meet potential strategic and operational partners, as well as suppliers, manufacturers, customers, and other partners in the territory.
The company believes that an HIV/AIDS therapy being developed by ReceptoPharm, a Nutra Pharma holding, may be of particular interest to potential Chinese partners.
The Chinese government recently announced that it has 840,000 HIV/AIDS cases among its population of 1.3 billion people, but experts say at least one million rural inhabitants were infected from contaminated needles when donating blood in the central province of Henan alone. Some experts have warned that unless preventative measures are taken the Chinese HIV population could reach 10 million by 2010.
NanoLogix, another holding of Nutra Pharma, is engaged in the research and development of diagnostic test kits to be used for the rapid identification of infectious human diseases such as tuberculosis and mycobacterium avium-intracellulare.
“The therapeutic and diagnostic platforms that are being developed by ReceptoPharm and NanoLogix have the potential to allow people in China to live longer and healthier lives,” remarked Rik Deitsch, Nutra Pharma’s CEO. “We are excited to be working with Xinhua Finance to create critical strategic relationships in China and Asia that may allow us to make inroads that would otherwise be difficult to make as a non-Chinese company.”